Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Picato 0.05% for basal cell carcinoma
2017-004608-22Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Feb 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ingenol mebutate in basal cell carcinoma (BCC), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Complete clinical and histological remission. Started Feb 2018; status: completed.
02
Drugs
ingenol mebutate
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2017-004608-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004608-22.